SyB-0702

Drug Profile

SyB-0702

Alternative Names: PEG-ZnPP; SyB 0702

Latest Information Update: 27 Jun 2011

Price : $50

At a glance

  • Originator Sojo University
  • Developer SymBio Pharmaceuticals
  • Class
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 27 Jun 2011 SyB-0702 is available for licensing as of 27 Jun 2011. http://www.symbiopharma.com
  • 27 Jun 2011 Preclinical development in Solid tumours is ongoing in Japan
  • 15 Sep 2007 Preclinical trials in Solid tumours in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top